Literature DB >> 10347097

Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis.

K N Cowan1, P L Jones, M Rabinovitch.   

Abstract

Increased elastase activity and deposition of the matrix glycoprotein tenascin-C (TN), codistributing with proliferating smooth muscle cells (SMCs), are features of pulmonary vascular disease. In pulmonary artery (PA) SMC cultures, TN is regulated by matrix metalloproteinases (MMPs) and mechanical stress. On attached collagen gels, MMPs upregulate TN, leading to SMC proliferation, whereas on floating collagen, reduced MMPs suppress TN and induce SMC apoptosis. We now investigate the response of SMCs in the whole vessel by comparing attached and floating conditions using either normal PAs derived from juvenile pigs or normal or hypertrophied rat PAs that were embedded in collagen gels for 8 days. Normal porcine PAs in attached collagen gels were characterized by increasing activity of MMP-2 and MMP-9 assessed by zymography and TN deposition detected by Western immunoblotting and densitometric analysis of immunoreactivity. PAs on floating collagen showed reduced activity of both MMPs and deposition of TN. Tenascin-rich foci were associated with proliferating cell nuclear antigen immunoreactivity, and TN-poor areas with apoptosis, by terminal deoxynucleotidyl transferase-mediated nick end labeling assay, but no difference in wall thickness was observed. Although normal rat PAs were similar to piglet vessels, hypertrophied rat PAs showed an amplified response. Increased elastase, MMP-2, TN, and elastin deposition, as well as SMC proliferating cell nuclear antigen positivity, correlated with progressive medial thickening on attached collagen, whereas reduced MMP-2, elastase, TN, and induction of SMC apoptosis accompanied regression of the thickened media on floating collagen. In showing that hypertrophied SMCs in the intact vessel can be made to apoptose and that resorption of extracellular matrix can be achieved by inhibition of elastase and MMPs, our study suggests novel strategies to reverse vascular disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10347097     DOI: 10.1161/01.res.84.10.1223

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  23 in total

1.  Effect of short-term organoid culture on the pharmaco-mechanical properties of rat extra- and intrapulmonary arteries.

Authors:  Christelle Guibert; Jean Pierre Savineau; Huguette Crevel; Roger Marthan; Eric Rousseau
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

2.  Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury.

Authors:  Miao Wang; Kaori Ihida-Stansbury; Devashish Kothapalli; Mathieu C Tamby; Zhou Yu; Lihong Chen; Gregory Grant; Yan Cheng; John A Lawson; Richard K Assoian; Peter L Jones; Garret A Fitzgerald
Journal:  Circulation       Date:  2011-01-31       Impact factor: 29.690

3.  Regulation of Bcl-xL expression in lung vascular smooth muscle.

Authors:  Yuichiro J Suzuki; Hiroko Nagase; Chi Ming Wong; Shilpashree Vinod Kumar; Vivek Jain; Ah-Mee Park; Regina M Day
Journal:  Am J Respir Cell Mol Biol       Date:  2007-02-01       Impact factor: 6.914

Review 4.  Novel strategy for treatment of pulmonary arterial hypertension: enhancement of apoptosis.

Authors:  Jing-bin Huang; Ying-long Liu; Pei-wu Sun; Xiao-dong Lv; Kong Bo; Xiang-ming Fan
Journal:  Lung       Date:  2010-03-06       Impact factor: 2.584

5.  Elafin in pulmonary arterial hypertension. Beyond targeting elastases.

Authors:  Hyung J Chun; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2015-06-01       Impact factor: 21.405

6.  Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease.

Authors:  K N Cowan; P L Jones; M Rabinovitch
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

7.  Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling.

Authors:  Nils P Nickel; Edda Spiekerkoetter; Mingxia Gu; Caiyun G Li; Hai Li; Mark Kaschwich; Isabel Diebold; Jan K Hennigs; Ki-Yoon Kim; Kazuya Miyagawa; Lingli Wang; Aiqin Cao; Silin Sa; Xinguo Jiang; Raymond W Stockstill; Mark R Nicolls; Roham T Zamanian; Richard D Bland; Marlene Rabinovitch
Journal:  Am J Respir Crit Care Med       Date:  2015-06-01       Impact factor: 21.405

8.  Serum tenascin-C level is associated with coronary plaque rupture in patients with acute coronary syndrome.

Authors:  Nobuo Sakamoto; Yasuto Hoshino; Tomofumi Misaka; Hiroyuki Mizukami; Satoshi Suzuki; Koichi Sugimoto; Takayoshi Yamaki; Hiroyuki Kunii; Kazuhiko Nakazato; Hitoshi Suzuki; Shu-ichi Saitoh; Yasuchika Takeishi
Journal:  Heart Vessels       Date:  2013-03-27       Impact factor: 2.037

Review 9.  Novel approaches to treat experimental pulmonary arterial hypertension: a review.

Authors:  S Umar; P Steendijk; D L Ypey; D E Atsma; E E van der Wall; M J Schalij; A van der Laarse
Journal:  J Biomed Biotechnol       Date:  2010-03-22

10.  Morphometric analysis of the lung vasculature after extracorporeal membrane oxygenation treatment for pulmonary hypertension in newborns.

Authors:  Arno van Heijst; Remco Haasdijk; Freek Groenman; Frans van der Staak; Christina Hulsbergen-van de Kaa; Ronald de Krijger; Dick Tibboel
Journal:  Virchows Arch       Date:  2004-06-03       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.